Reporting of adverse events ONLY

Patients should always seek the advice of a doctor or pharmacist in case of adverse events. If you wish to report an adverse event to ELC Group s.r.o., please find the contact information below:

Telephone: 00420 224 910 672 (from 09.00-17.30 CET)
Cell phone: 00420 723 694 460 (non-stop 24/7)

Hlášení nežádoucích príhod

Pacienti by meli vždy požádat o radu svého lékare nebo lékárníka v prípade výskytu nežádoucích príhod. Pokud chcete nahlásit nežádoucí príhodu spolecnosti ELC Group s r.o., prosím využijte kontaktních údaju níže:

Telefon: 00420 224 910 672 (09.00-17.30 CET)
Mobilní telefon: 00420 723 694 460 (non-stop 24/7)


From Concept to Commercialisation is one of the key partnership areas in which ELC GROUP is creating its fast-growing success.
From the development stage through to the implementation of clinical trials, completion of product registration, and successful marketing of the product, ELC GROUP aligns itself as a strategic partner to help pharmaceutical companies achieve their healthcare goals.


Fast-growing regulatory affairs service provider ELC Group expands corporate presence in Czech Republic - 24th February 2015

Major contract wins in China and US fuel latest move into larger premises in Prague More

ELC GROUP to present at “Regulatory & Legal Affairs in Russia 2015” Conference - 2nd February 2015

Dr. Parvinder Punia, Senior regulatory expert will present “European experience of harmonising the pharmaceutical market” at Moscow conference on February 10th 2015 More

Pharma eReport delivers V5-compliant solution to help MAHs meet December 31st XEVMPD resubmission deadline - 15th September 2014

Centrality software is fully compliant with EMA V5 schema updates and available now to pharmaceutical Marketing Authorisation Holders More

Case Studies

Referral Management Service

When this generic international pharmaceutical company found its promising pan-European license application suddenly encountering an unexpected problem, it turned to ELC to navigate the complex referral process and get back on track to achieve the all-important approvals it needed to go to market.

Scientific Advice Service

When an Asia-based pharmaceutical company wanted to speed time-to-market for its generic to a leading brand-name drug, it engaged ELC Group to help to get the product successfully launched in European markets on its first submission – and as the first in its market.

Complete Pharmacovigilance

A generic pharmaceutical company looked to ELC Group’s experience and expert knowledge to help reduce operational costs, meet key regulatory deadlines and ensure continuing compliance across its global portfolio of products.